Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation
Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated
Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation. An Open-Label Phase 1b/2 Study of Binimetinib Administered in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Patients With Previously Treated Microsatellite-Stable (MSS) Metastatic Colorectal Cancer With RAS Mutation
Category & Conditions: Cancer
Medicine: MEKTOVI® TABLETS(BINIMETINIB)
OPDIVO®(NIVOLUMAB)
YERVOY®(IPILIMUMAB)
ClinicalTrials.gov Identifier (NCT): NCT03271047
Protocol ID: C4211004
PrintDownloadOpen Plain Language Summary Result: Click here